Skip to main content

Table 8 Overall survival and progression-free survival of patients with tumors of differing diameters

From: The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma

Tumor diameter

OS (months)

P

PFS (months)

P

Median

95% CI

Median

95% CI

Group 1

  < 5 cm

44

21.624–66.376

0.004

8

5.633–10.367

0.268

  ≥ 5 cm

17

11.806–22.194

7

4.915–9.085

Group 2

  < 7 cm

38

20.228–55.772

0.002

9

6.003–11.997

0.012

  ≥ 7 cm

14

10.409–17.591

5

3.007–6.993

  1. CI confidence interval, OS overall survival, PFS progressive free survival
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us